Back to search results

Finerenone for Heart Failure

This study is testing a drug called finerenone to see if it can help people with heart failure (when your heart can't pump enough blood). You might be able to join if you have heart failure with reduced ejection fraction (HFrEF) and cannot take other similar medications (steroidal mineralocorticoid receptor antagonists or sMRA) due to intolerance or other reasons. Researchers want to see if finerenone can reduce serious heart problems like cardiovascular death or heart failure events, and they will also track any side effects. The study is currently recruiting about 2600 participants.

Study design
This is an international study where participants are randomly assigned to receive either finerenone or a placebo (an inactive pill), and neither you nor your doctor will know which one you are receiving. It aims to enroll 2600 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to about 30 months to track cardiovascular events and side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06033950

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Recruiting
PHASE3Ages 18+InterventionalTreatment
Colorado Prevention Center
~2,600 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:FinerenonePlacebo

At a glance

Recruiting sites
176 of 176 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first occurrence of cardiovascular (CV) death or HF event.
Measured over Ongoing, up to ~30 months
+2 more outcomes measured

Conditions

Heart Failure

Explore related trials

Heart Failure

NCT06033950

Where you'd take part

This study runs at 176 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • A Coruña, Galicia Investigative Site FIN-38004

    A Coruña, Galicia, Spainstudy coordinator listed

    Recruiting

  • Alexandroupolis, Evros Investigative Site FIN-33012

    Alexandroupoli, Evros, Greecestudy coordinator listed

    Recruiting

  • Athens, Attica Investigative Site FIN-33004

    Athens, Attica, Greecestudy coordinator listed

    Recruiting

  • Athens, Attica Investigative Site FIN-33009

    Athens, Attica, Greecestudy coordinator listed

    Recruiting

  • Barcelona Investigative Site FIN-38010

    Barcelona, Spainstudy coordinator listed

    Recruiting

  • Belo Horizonte, Minas Gerais

    Belo Horizonte, Minas Gerais, Brazilstudy coordinator listed

    Recruiting

  • Belo Horizonte, Minas Gerais Investigative Site FIN-21079

    Belo Horizonte, Minas Gerais, Brazilstudy coordinator listed

    Recruiting

  • Bradenton, FL Investigative Site FIN-10125

    Bradenton, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Marc Bonaca
[email protected]
(303) 860-9900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations
Age ≥18 years or legal age of majority if \>18 years in the participant's country of residence
Symptomatic HFrEF per protocol defined criteria
Not on sMRA due to history of intolerance, contraindication, or ineligibility for treatment
Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)

Exclusion

Treatment with non-steroidal MRA (nsMRA)
Documented prior history of severe hyperkalemia in the setting of MRA use
eGFR \< 25 mL/min/1.73m² and / or potassium \> 5.0 mmol/L
Acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days or planned
Prior or planned heart transplant
Hemodynamically significant (severe) uncorrected primary cardiac valvular disease considered by the investigator to be the primary cause of heart failure
Symptomatic bradycardia or second- or third-degree heart block without a pacemaker
Cardiomyopathy due to known acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction
Probable alternative cause of participant's HF
Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, or moderate or potent CYP3A4 inducers
Known hypersensitivity to the IP (active substance or excipients)
Any other condition or therapy which would make the participant unsuitable for the study
Concurrent or previous participation in another interventional clinical study using an investigational agent within 30 days prior to randomization

What this trial measures

  • Time to first occurrence of cardiovascular (CV) death or HF event.Ongoing, up to ~30 months

    \- Time to first CV death or HF event with finerenone compared to placebo.

  • Number of serious adverse eventsOngoing, up to ~30 months

    \- Serious adverse events (excluding efficacy endpoints) with finerenone compared to placebo.

  • Number of adverse events leading to discontinuation of study drug.Ongoing, up to ~30 months

    \- Number of adverse events leading to discontinuation of investigational product with finerenone compared to placebo.